Opioid Product Sponsors Eye REMS Fixes To Boost Prescriber Education Uptake
This article was originally published in The Pink Sheet Daily
Program missed goal for number of doctors trained; industry says changes in FDA's blueprint and better coordination of federally sponsored education programs are needed to enhance awareness of the risk management plan.
You may also be interested in...
FDA's Opioid REMS Review Puts Brakes On Mandatory Education Push
Requiring training and certification for extended-release opioids would involve at least 320,000 prescribers and impact 21 million outpatient prescriptions, reviewers note in a briefing memo that is more skeptical of the mandatory approach than FDA's leadership has been.
Intercept’s OCA In NASH: When Hitting Surrogate Endpoint Is Not Enough For Accelerated Approval
Although US FDA reaffirmed its support of surrogate endpoints described in a 2018 draft guidance on NASH fibrosis, advisory committee members questioned the link to clinical benefit and said obeticholic acid’s serious risks made it difficult to consider the effect on the surrogate in a vacuum.
Intercept’s OCA Facing Extended Approval Wait In NASH As Known Risks Swamp Uncertain Benefits
Obeticholic acid clinical outcomes data from Phase III trial are needed before approval, US FDA advisory committee says, but Intercept suggests future of ongoing study is in doubt if accelerated approval in nonalcoholic steatohepatitis is not forthcoming now.